Pipeline & Programs
Powered by great science
We are utilizing our deep knowledge of drug mechanisms to develop medicines with the potential to provide meaningful differences for people living with psychiatric and neurological conditions.
Pipeline
Our extensive knowledge of how drugs work in the central nervous system fuels our drug discovery and clinical efforts, as we work towards our goal of developing transformative medicines. Our intimate understanding of the biology of muscarinic receptors has propelled our research toward finding novel mechanisms for treating diseases through appropriate activation of the cholinergic system, starting with our lead candidate KarXT.
Product Candidate | Indication |
Preclinical
Phase 1
Phase 2
Phase 3
Registration
|
---|---|---|
KarXT (xanomeline-trospium) M1-M4 muscarinic agonist |
Schizophrenia
|
|
Schizophrenia Adjunctive therapy
|
||
Psychosis in Alzheimer's disease
|
||
KAR-2618* TRPC4/5 inhibitor |
Mood & anxiety disorders
|
|
KAR-201 Muscarinic-targeted drug candidate |
Undisclosed
|
|
KAR-301 Muscarinic-targeted drug candidate |
Undisclosed
|
|
KAR-401 Muscarinic-targeted drug candidate |
Undisclosed
|
|
KAR-501 Target-agnostic drug candidate† |
Undisclosed
|
†In collaboration with PsychoGenics
KarXT
Clinical trials
Partnerships & collaborations
Scientific & medical research
Expanded Access Policy
Karuna Therapeutics does not currently accept or grant requests for expanded access to any of its investigational drugs outside of clinical trials. To learn more about our ongoing clinical programs, please visit our ClinicalTrials.gov webpage.